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Background: The study was designed to evaluate the effects of moderate prosthesis-patient mismatch (defined
as 0.65 cm2/m2 < indexed effective orifice area ≤ 0.85 cm2/m2) on midterm outcomes after isolated aortic valve
replacement with a 17-mm St. Jude Medical Regent valve in a large series of patients, and to determine if these
effects are influenced by patient confounding variables.
Methods: One-hundred and six patients with and without moderate prosthesis-patient mismatch early after
implantation of a 17-mm Regent valve at aortic position were included. Both clinical and echocardiographic
assessments were performed preoperatively, at discharge and during follow-up period (mean follow-up time
52.6 ± 11.9 months).
Results: The prevalence of moderate prosthesis-patient mismatch was documented in 46 patients (43.4%) at discharge.
During the follow-up period, no difference in the regression of left ventricular mass, decrease of transvalvular pressure
gradients, mortality and prosthesis-related complications was observed between patients with and without moderate
prosthesis-patient mismatch. After adjustment for several risk factors, moderate prosthesis-patient mismatch was
associated with increased midterm mortality in patients with baseline left ventricular ejection fraction < 50% (HR: 1.80,
p = 0.02), but with normal prognosis in those with preserved LV function. Younger age (cut off value = 65 years)
was not an independent predictor of increased midterm mortality and valve-related complications in patients
with moderate prosthesis-patient mismatch.
Conclusions: Moderate prosthesis-patient mismatch after aortic valve replacement with a small mechanical prosthesis
is associated with increased mortality and adverse events in patients with pre-existing left ventricular dysfunction.
Selected patients with small aortic annulus can experience satisfactory clinical improvements and midterm survival
after aortic valve replacement with a 17-mm Regent valve.
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Dealing with a small aortic root of less than 19 mm during
aortic valve replacement (AVR) remains a challenging
scenario for the cardiac surgeons with regard to operative
techniques and selection of appropriate prosthesis [1-4].
As implantation of a smaller prosthetic valve without
adequate effective orifice area index (EOAi) may predispose
to unfavorable outcomes, several strategies at the time* Correspondence: eyzhang@outlook.com
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stated.of operation have been developed to avoid the feared
prosthesis-patient mismatch (P-PtM, defined as EOAi ≤
0.85 cm2/m2) [5-8], including the use of aortic root
enlargement/replacement procedures with a larger pros-
thesis (eg. a stentless bioprosthesis or a new generation
of stented bioprosthesis) or modern bileaflet mechanical
valve implanted in the supra-annular position. However,
these strategies are technically more difficult, require
longer cardiopulmonary bypass times, and fail to point
uniformly toward an improved clinical outcome [2,3].
The 17-mm St. Jude Medical Regent (SJMR) valve with
an improved hemodynamic profile is regarded as a validThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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Although the Regent valves offer a larger EOA than
that of conventional prosthetic valves, the occurrence
of P-PtM in patients with 17-mm SJMR valves is reported
as high as 31%-94.1% [1,2,9-11]. The main hemodynamic
consequence of P-PtM, especially the severe P-PtM
(EOAi ≤ 0.65 cm2/m2), is to generate higher than
expected transvalvular gradients, which is responsible
for incomplete left ventricular mass (LVM) regression,
increased valve-related complications and postoperative
mortality [6,7,12-15]. However, controversies still exist
as to the impacts of early postoperative moderate P-PtM
(0.65 cm2/m2 < EOAi ≤ 0.85 cm2/m2) on late outcomes
[5-7,12-15]. Moreover, reported experience with 17-mm
Regent valves in a large series of patients are rare. Thus,
the objective of this study was to evaluate the effects of
moderate P-PtM on midterm outcomes after isolated AVR
with a 17-mm SJMR valve and to determine if these effects
are modulated by patient’s confounding variables.
Methods
Patient profile
From December 2006 and June 2012, consecutive 114
patients underwent isolated AVR with a 17-mm SJMR
valve in our hospital. Moderate P-PtM (0.65 cm2/m2 <
EOAi ≤ 0.85 cm2/m2) was present in 106 patients and
severe P-PtM (EOAi <0.65 cm2/m2) in 8 patients. All the
data were prospectively collected and retrospectively
analyzed. One hundred and six patients were divided
into two subsets according to the presence of moderate
P-PtM at discharge. The study group comprised 79
women (74.5%) and 27 men (25.5%) with a mean age of
52.5 ± 8.6 years. Mean body surface area (BSA) was
1.56 ± 0.16 m2. Fifty-four patients (50.9%) were in New
York Heart Functional (NYHA) class III/IV preoperatively.
Our investigation, including follow-up studies, was
approved by the Ethical Review Board of West China
Hospital in compliance with the Declaration of Helsinki.
All patients had previously granted permission for the
anonymous use of their medical information. The demo-
graphic and clinical data of all patients are summarized
in Table 1.
Echocardiographic measurements and calculations
Echocardiographic measurements included M-mode, two-
dimensional, continuous wave, and Doppler analysis.
Standard M-mode cardiac dimensions were collected
according to the criteria of the American Society of
Echocardiography. All Doppler measurements were
obtained as the average of at least 3 cycles in patients
with sinus rhythm or more than 5 cycles in those with
atrial fibrillation. The following parameters were collected:
end-diastolic septal thickness, left ventricular end-diastolic
dimension, and end-diastolic left ventricular posterior wallthickness. The peak and mean transvalvular gradients
were calculated by the complete Bernoulli equation. The
mass of the left ventricle (LV) was estimated according to
the joint recommendations of the American and European
associations of echocardiography using Devereux’s [16]
and indexed to BSA (LVMI). The effective orifice area
(EOA) was determined by the standard continuity equation
[(LVOT2 × 0.785 × TVI1)/TVI2)], where LVOT is the diam-
eter of the left ventricular outflow tract, and TVI1 and TVI2
are the time-velocity integrals at the LVOT and across
the aortic valve, respectively. The measured EOAi, a
valid parameter for quantification of the severity of P-PtM,
was calculated by dividing the EOA by the BSA. Also, the
projected EOAi was derived from the published normal
in vivo EOA values for the 17 mm SJMR valve and
indexed to BSA [12]. Unless specified otherwise, EOAi
throughout this article indicates measured EOAi.
Operative techniques and anticoagulation therapy
All patients were approached through a median sternot-
omy. Cardiopulmonary bypass was initiated after cannula-
tion of the ascending aorta, superior vena cava and inferior
vena cava. The operation was performed with moderate
hypothermia and use of antegrade cold blood cardioplegia.
No patient underwent aortic annulus enlargement or root
replacement. After removal of the diseased leaflets and
calcifications from the annulus, the size of the prosthesis
was determined according to the diameter of the aortic
annulus, which was measured with manufacturer’s sizers
(St. Jude Medical, USA). The 17-mm SJMR were then im-
planted in the supra-annular position using 2–0 interrupted
polyester –non-everting mattress sutures in all patients.
After the first postoperative day, patients received oral
warfarin sodium at daily updated dosages according to
the international normalized ratio of prothrombin time
(PT-INR), with a target value maintained between 1.5
and 2.0.
Follow-up
Clinical follow-up was updated to June 2013 through direct
hospital visits and structured telephone interviews for
all survivors. Both clinical and echocardiographic assess-
ments were scheduled by protocol at discharge (mean
7.4 ± 2.1 days), sixth postoperative month and yearly there-
after. Follow-up transthoracic echocardiographic data were
obtained for 96 (93.2%) of the 103 discharged patients
at 45.8 ± 8.8 months after primary surgery. The clinical
follow-up was 97.1% complete. Mean follow-up time
was 52.6 ± 11.9 months (median, 50.5 months; range,
14-74 months). In case of new-onset symptoms, additional
echo were performed, and the patient’s follow-up charts
were updated accordingly. The valve-related complications
were defined according to the guidelines for reporting
after cardiac valve interventions [17].
Table 1 Baseline clinical characteristics and operative data in patients with and without moderate prosthesis-patient
mismatch (P-PtM)
Variables Overall Non-PPM Moderate PPM *p value
(n = 106) (n = 58) (n = 45)
Age, years 52.5 ± 8.6 52.1 ± 10.2 53.0 ± 12.7 0.398
Age group, years
≤ 65 56(52.8%) 30(51.7%) 25(55.6%) 0.831
> 65 50(47.2%) 28(48.3%) 20(44.4%) 0.815
Female sex 79 (74.5%) 53 (91.4%) 23 (51.1%) 0.047
Height (m) 1.65 ± 0.09 1.62 ± 0.05 1.69 ± 0.04 0.106
Body surface area (m2) 1.56 ± 0.16 1.48 ± 0.09 1.66 ± 0.16 0.038
Projected EOAI (cm2/m2) 0.90 ± 0.04 0.95 ± 0.03 0.84 ± 0.02 0.041
Body mass index (kg/ m2) 22.9 ± 2.8 22.1 ± 1.1 22.9 ± 2.7 0.109
Pre-NYHA class
I/II 52(49.1%) 35(60.3%) 16(35.6%) 0.097
III/IV 54 (50.9%) 23(39.7%) 29(64.4%) 0.105
Ejection fraction
≥50% 45(44.3%) 30(51.7%) 15(33.3%) 0.159
<50% 58(55.7%) 28(48.3%) 30(66.7%) 0.207
Atrial fibrillation 15 (14.2%) 9 (15.5%) 4(8.9%) 0.281
Chronic heart failure 13(12.3%) 5(8.6%) 8(17.8%) 0.178
Ischemic heart disease 37(19.8%) 21(36.2%) 13(28.9%) 0.362
Renal insufficiency 8(7.5%) 5(8.6%) 3(6.7%) 0.518
Hypertension 36 (34.0%) 21(36.2%) 15(33.3%) 0.496
Diabetes 29 (27.3%) 10(17.2%) 16(35.6%) 0.079
Valve pathology
Degenerative 33 (31.1%) 18 (31.0%) 14(31.1%) 0.557
Rheumatic 53 (50.0%) 27 (46.6%) 25(55.6%) 0.364
Infective 3 (2.8%) 2(3.4%) 1(2.2%) 0.599
CPB time (min) 108 ± 32 105 ± 21 110 ± 35 0.541
Cross-clamp time (min) 90 ± 23 87 ± 18 92 ± 27 0.617
In-hospital death 3(2.8%) - - -
NYHA, New York Heart Association; CPB, cardiopulmonary bypass; EOAI, effective orifice area index; *Data were compared between the non-PPM group and the
moderate PPM group.
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Continuous variables are presented as mean ± standard
deviation and categorical data as percentages unless
otherwise specified. Differences in pre- and postoperative
echocardiographic data for all patients were compared
and analyzed by paired Student’s t-test. Differences in
patients with and without moderate P-PtM early after
surgery were analyzed by χ2, Fisher exact or unpaired
Student’s t test as appropriate. Pearson’s coefficient was
used to analyze the correlation between the projected
EOAi and the measured EOAi. The actuarial survival
rate and ratio of patients without valve-related compli-
cations were calculated by the Kaplan-Meier methodand compared between groups by using a log-rank test.
Cox proportional-hazards regression model was used
to determine whether the occurrence of moderate P-
PtM was associated with increased risk of valve-related
complications and intermediate-term mortality. Variables
with a univariate p < 0.2 or those of known clinical import-
ance for survival and adverse events were submitted to
the multivariate models to calculate hazards ratios (HR)
and its 95% confidence intervals (CI). All p values less
than 0.05 were considered statistically significant. All
statistical analyses were performed using Statistical Pack-
age for Social Sciences version 16.0 (SPSS Inc, Chicago,
IL, USA).
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Operative morbidity and mortality
In-hospital mortality was 2.8% (3 patients). The causes of
the in-hospital death were cerebral infarction (1 patient),
respiratory failure (1 patient) and low cardiac output
syndrome (1 patient). The early postoperative period was
complicated in two patients by atrioventricular block
requiring pacemaker implantation. Univariate analysis
identified left ventricular ejection fraction (LVEF) <35% as
an independent predictor of in-hospital mortality (HR
1.32, 95% CI: 1.09 to 1.78, p = 0.041). However, multivari-
able analysis yielded no significant predictor of early post-
operative death. Two patients experienced perioperative
intra-aortic balloon pumping for hemodynamic instability.
Clinical follow-up and valve-related complications
During follow-up, NYHA functional class improved in the
entire cohort and the improvement was not significantly
different between the groups with and without moderate
P-PtM. Three patients were readmitted due to prosthetic
endocarditis, two patients were reoperated for paravalvular
leakage, and one patient experienced cerebral hemorrhage.
Late cerebral infarction, prosthetic thrombosis, and struc-
tural failure of the mechanical valves did not occur in
any patient during follow-up. Freedom from valve-related
complications at 1-year, 3-year, and 5-year was 97.2%,
94.3%, and 89.9%, respectively (Figure 1A). Univariate
analysis identified atrial fibrillation, diabetes and renal
insufficiency were associated with an increased risk of
postoperative valve-related complications, and only diabetes
was identified as the independent predictor of valve-related
complications by multivariate analysis (Table 2). Freedom
from reoperation at an average of 52.6 ± 11.9 months after
primary AVR was 98.0%. Long-term survival and freedom
from cardiovascular death are shown in Figure 1B. Of
the 103 survivors, 12 patients (10.6%) died during the
follow-up period: myocardium infarction (n = 2), malig-
nancy (n = 2), heart failure (n = 2), sepsis (n = 2), pneumo-
nia (n = 1), renal failure (n = 1), unknown (n = 2). Actuarial
1-year, 3-year, and 5-year survival rate were 96.2%, 89.4%,
and 80.5%, respectively. Univariate analysis revealed age,Figure 1 (A) Freedom from valve-related complications; (B) Midterm spreoperative LVEF <35%, diabetes, renal insufficiency, and
a concomitant coronary surgery as predictors of overall
mortality (including in-hospital death). Multivariate ana-
lysis showed diabetes and preoperative LVEF <35% to
be the independent predictors of the postoperative
death (Figure 2). Freedom from cardiovascular death at
1-year, 3-year, and 5-year was 98.1%, 95.9%, and 90.2%,
respectively. As for the 8 patients with severe P-PtM at
discharge, only one anticoagulation-related complication
was observed and no cardiovascular death was observed
during an average of 48.7 ±8.9 months follow-up.
Echocardiographic follow-up
The baseline and postoperative echocardiographic data of
all patients are reported in Table 3. A significant reduction
in peak and mean transvalvular gradient was observed in
all patients, with a mean difference versus preoperative
values of 82.9 ± 29.5 mmHg and 50.2 ± 16.8 mmHg, re-
spectively. Follow-up echocardiography also revealed a
significant regression of LVMI, decreasing from preopera-
tive values of 196.1 ± 44.3 g/m2 to 118.9 ± 30.8 g/m2 after
surgery. During follow-up, the mean EOA and EOAi were
significantly increased compared with preoperative values.
No significant difference between preoperative and post-
operative LVEF was observed.
Relationship between the projected EOAi and
measured EOAi
The projected EOAi of the two groups was calculated
and significant difference between groups was observed
(Table 1). A significant correlation between the projected
EOAi and measured EOAi was observed (r = 0.74, p =
0.03). However, in the subgroup analysis of patients with
LVEF < 50% (n = 58), the projected EOAi moderately cor-
related with the measured EOAi (r = 0.59, p = 0.051), and
the projected EOAi has a sensitivity of 74% and specificity
of 55% for predicting moderate P-PtM postoperatively.
Effects of P-PtM on clinical and echocardiographic variables
The prevalence of moderate P-PtM, defined as an EOAI
ranging from 0.65 cm2/m2 to 0.85 cm2/m2, wasurvival and freedom from cardiac death.
Table 2 Univariate and multivariate analysis for independent predictors of valve-related complications and mortality
Variables Valve-related complications Overall mortality
Univariate Multivariate Univariate Multivariate
(P value) HR[95% CI], P value (P value) HR[95% CI], P value
< 65 years 0.165 3.4[0.6-8.1], 0.320 0.108 1.6[0.8-2.7], 0.245
≥ 65years 0.087 0.9[0.2-1.6], 0.194 0.047 1.3[1.0-1.7], 0.071
Sex: male 0.548 - 0.876 -
Body mass index 0.265 - 0.178 -
I/II 0.374 - 0.217 -
III/IV 0.081 1.5[0.9-2.8], 0.075 0.098 1.4[1.0-1.6], 0.059
>50% 0.727 - 0.324 -
35%-50% 0.165 2.0[1.1-3.7], 0.234 0.061 1.3[0.9-1.7], 0.088
<35% 0.071 1.3[0.7-1.9], 0.128 <0.001 2.0[1.1-3.7], 0.021
>0.85 cm2/m2 0.791 - 0.564 -
>0.65 to <0.85 cm2/m2 0.108 1.2[0.9-1.4], 0.144 0.145 1.2[0.9-1.6], 0.188
Atrial fibrillation 0.013 1.1[0.5-2.7], 0.088 0.076 1.3[0.2-2.2], 0.064
Congestive heart failure 0.102 1.6[0.7-2.9], 0.268 0.128 2.2[0.6-2.1], 0.091
Renal insufficiency 0.041 2.3[0.8-4.3], 0.099 0.027 1.6[0.3-3.3], 0.054
Hypertension 0.323 - 0.279 -
Diabetes mellitus <0.001 3.2[1.8-6.4], 0.015 <0.001 3.8[2.0-5.9], 0.002
Chronic lung disease 0.094 1.7[0.6-3.3], 0.102 0.211 1.6[0.1-1.8], 0.069
Concomitant CABG 0.072 1.6[0.8-4.1], 0.109 0.033 3.1[0.9-8.7], 0.084
CPB time (min) 0.382 1.0[0.8-1.2], 0.502 0.089 1.6[0.8-2.3], 0.069
Cross-clamp time (min) 0.687 1.0[0.3-3.5], 0.751 0.139 1.5[1.1-2.1], 0.078
CABG, coronary artery bypass grafting; CI, confidence intervals; HR, hazard ratio; other abbreviations as in Tables 1.
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parison to the patients without P-PtM, the group of pa-
tients with moderate P-PtM had a significantly greater
mean BSA, proportion of males and bicuspid aortic
valve disease (Table 1). As demonstrated in Table 3, the
EOAI at discharge were significantly lower in patients
with moderate P-PtM than in those without P-PtM.
During the follow-up period, no difference in the regres-
sion of LVMI, decrease of transvalvular pressure gradients,
valve-related complications and overall survival (Figure 2A
and Figure 2B) between groups was observed. However,
moderate P-PtM was associated with increased midterm
mortality in patients with LV ejection fraction < 50%
(HR 1.80, 95% CI: 1.32 to 2.46, p = 0.02), but not in
patients with preserved LV systolic function (Figure 2C
and Figure 2D). Young age (< 65 years) was not associated
with an increased risk of midterm mortality in patients with
moderate P-PtM at discharge (Figure 2E and Figure 2F).
Discussion
The present study demonstrated satisfactory outcomes
of AVR with 17-mm SJMR valve in terms of midterm
survival, physical capacity and hemodynamic performances.
The data of our study corroborate with previous studiesindicating the presence of moderate P-PtM early after
surgery was not a risk factor of intermediate mortality.
However, in our subgroup analysis, moderate P-PtM
was associated with a significant decrease in overall
survival in patients with impaired LV systolic function.
These findings emphasize the importance of a prospective
strategy for selection of appropriate AVR candidate
and operative methods to achieve satisfactory results
in patients with small aortic annulus.
Although the 17-mm SJMR valve is a new generation of
aortic prosthesis with an improved hemodynamic profile,
the beneficial effects of implanting this mechanical valve
in patients with small aortic roots remain unclear, par-
ticularly in young patients and in the mid- to long-term.
Okamura group reported a cohort of elderly patients
(mean age >70 years) demonstrating satisfactory clinical
improvement and regression of LVM after AVR with the
17-mm SJMR [2,10,11]. Similarly, a series of studies dem-
onstrated favorable clinical outcomes, as well as improved
hemodynamic performance both at rest and under an
exercise load [2,8-11,18,19], after AVR with a 17-mm
SJMR valve. However, these studies are mostly presented
with a small number of elderly patients during a relatively
short follow-up period. As the moderate P-PtM frequently
Figure 2 Impact of moderate prosthesis-patient mismatch on postoperative outcomes: (A) Overall valve-related complications;
(B) Overall survival; (C) Preoperative left ventricular ejection fraction (LVEF) <50%; (D) LVEF≥ 50%; (E) Patients < 65 years old;
(F) Patients ≥ 65 years old.
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[1,2,9-11], its potential adverse effects on postoperative
outcomes are not well characterized. Therefore, we need
to investigate furtherly into the safety and effectiveness of
the 17-mm SJMR in a large number of patients of all ages.
Apart from its improved hemodynamic performances,
the 17-mm SJMR valve was applied in this population
for several other reasons. First, our patients presented
with a relatively high-risk characteristics [high proportion
of female patients (74.5%), NYHA class III/IV (50.9%),
LVEF < 50% (55.7%), and concomitant coronary surgery
(34.9%)], and therefore a “quick and simple” procedure
was required to reduce myocardial ischemic time. It is
clinically evident that a prolonged aortic cross-clamp time
is one of the most important risk factors for post-AVR
adverse events [3,4,6,7]. Although aortic root enlargement
procedures or stentless prosthesis implantation are feasible
options for patients with small aortic annulus, these proce-
dures are technically more difficult and time consuming,
and may result in higher morbidity than simple valve
replacement, particularly in our patients who often have a
severe calcified aortic root due to rheumatic and degen-
erative etiologies (81.1%). Moreover, a series of studies
have clearly indicated that a better hemodynamic outcome
early after surgery in patients underwent aortic root en-
largement and AVR could not translate into an improvedpostoperative survival compared with patients with iso-
lated AVR [2-4].
An important finding of this study is that moderate P-
PtM is associated with increased postoperative mortality
in patients with LVEF < 50%, but with normal prognosis
in those with preserved ventricular function. Since patients
with impaired LV function are more vulnerable to the
excessive afterload imposed by P-PtM, it is reasonable
to find in our series that the follow-up mortality are
significantly increased in patients with a combination
of moderate P-PtM and impaired LV systolic function.
Studies from several groups also clearly indicated that
the influential role of moderate P-PtM on late survival
is more important in patients with reduced ventricular
reserve than in those with preserved LV function [12,13].
On the contrary, however, some others failed to identify
the moderate P-PtM as an independent predictor of valve-
related complication and mortality after AVR [15,19].
These compelling evidence may be partially explained
by the fact that investigators used different parameters
(eg. projected, geometric or in vivo measured EOAi)
to identify P-PtM and quantify its severity. As demon-
strated in the present study, using the projected EOAi
in predicting P-PtM in patients with LVEF < 50% has a
lower accuracy; therefore, the projected EOAi to
determine prediction and outcomes of P-PtM is of
Table 3 Echocardiographic preoperative and post-operative data
Variables Overall Non-PPM Moderate PPM p value*
(n = 103) (n = 58) (n = 45)
Preoperative data
Peak TVG (mmHg) 115.2 ± 38.7 121.4 ± 36.9 107.2 ± 31.8 0.362
Mean TVG (mmHg) 68.1 ± 21.9 71.2 ± 18.79 64.1 ± 26.8 0.381
LVMI (g/m2) 196.1 ± 44.3 201.7 ± 54.6 188.8 ± 68.4 0.154
EOAI (cm2/m2) 0.44 ± 0.18 0.42 ± 0.16 0.47 ± 0.08 0.631
Ejection fraction (%) 58.4 ± 11.9 59.8 ± 12.6 56.6 ± 9.9 0.184
Postoperative (at discharge) data
Peak TVG (mmHg) a31.8 ± 12.1 a28.7 ± 13.4 a35.8 ± 16.1 0.398
Mean TVG (mmHg) a17.2 ± 5.98 a16.3 ± 4.69 a18.4 ± 7.9 0.691
LVMI (g/m2) 170.8 ± 48.9 167.1 ± 39.1 175.6 ± 54.3 0.437
EOAI (cm2/m2) a0.91 ± 0.21 a1.01 ± 0.13 a0.78 ± 0.09 <0.01
Ejection fraction (%) 56.9 ± 15.4 58.1 ± 13.4 55.3 ± 10.9 0.697
Follow-up data
Peak TVG (mmHg) b32.3 ± 8.91 b29.6 ± 7.4 b35.1 ± 11.4 0.412
Mean TVG (mmHg) b17.9 ± 6.79 b16.8 ± 5.14 b19.3 ± 8.16 0.689
LVMI (g/m2) b118.9 ± 30.8 b117.1 ± 26.1 b121.2 ± 33.8 0.186
EOAI (cm2/m2) b0.96 ± 0.18 b0.99 ± 0.21 b0.92 ± 0.16 0.781
Ejection fraction (%) 60.1 ± 6.5 61.2 ± 7.1 58.7 ± 10.3 0.336
Reduction rate (%): preoperative to follow-up
Peak TVG (%) 72.0 ± 12.6 75.6 ± 9.9 67.3 ± 15.9 0.131
Mean TVG (%) 73.7 ± 8.9 76.4 ± 13.1 69.8 ± 12.5 0.152
LVMI (%) 39.4 ± 20.9 41.9 ± 18.4 35.8 ± 19.8 0.109
TVG, transvalvular gradients; LVMI, left ventricular mass index; other abbreviations as in Tables 1 and 2. *Data were compared between the non-PPM versus the
moderate PPM; aP < 0.05 for postoperative (at discharge) data versus preoperative data; bP < 0.05 for follow-up data versus preoperative data.
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and prevalence of moderate versus severe P-PtM in the
patient population, as well as the diversity of the im-
planted prosthesis and surgical approaches are believed
to contribute.
Previous studies have demonstrated that the influence of
P-PtM on postoperative outcomes is an age-dependent
phenomenon. As reported by Mohty et al. [12] and Moon
et al. [20], moderate -to- severe P-PTM was detrimental
to survival in young patients (<60 or 70 years of age), but
its impacts on older patients are negligible. These findings
might be related to the fact that younger patients are
generally more physically active and they indeed have
greater cardiac output requirements in relation to body
size. However, in our series, younger age (<65 years) was
not identified as an independent risk factor of increased
midterm mortality and valve-related complications in
patients with moderate P-PtM. A possible explanation
could be that the proportion of patients with bioprosthetic
valve in previous studies was as high as 67%-77.8%
[12,13]. As P-PtM is a significant risk factor for acceler-
ated degeneration of bioprosthetic heart valves [21],and bioprosthesis in younger patients may expose to
the progression of valvular degeneration for a longer
period of time, it seems very likely that the impact of
moderate P-PtM on postoperative outcomes is more
pronounced in younger patients than in older ones. In
addition, our insignificant result might be owing to the
limited numbers of the subgroup populations.
Some could argue that the use of mechanical prostheses
in AVR may potentially increase mortality and morbidity
compared with the use of bioprosthesis, particularly due
to anticoagulation–related complications [22]. However,
in the present study, which employed strict control of
PT-INR within a range of 1.5-2.0, only three patients
experienced anticoagulation-related adverse events, ac-
counting for a linearized rate of 0.2% per patient-year.
These complication rates are comparable to other reports
of patients who underwent bioprostheses implantation
[2,12,13,15]. According to the American College of Chest
Physicians guidelines [23], our anticoagulant level is lower
but is proved efficient in Chinese patients with mechanical
heart valve prostheses [24,25]. Similarly, investigators
from other Asian countries have demonstrated low
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with low intensity anticoagulant strategy, suggesting that
mechanical valves are not a risk factor for postopera-
tive adverse events with good control of PT-INR levels
(1.8-2.2) [2,9].
Study limitations
This study was subject to the limitations inherent to a
retrospective, nonrandomized comparison of clinical
data, so it is likely that a selection bias or unidentified
confounders might have influenced the results. In the
present study, moderate P-PtM was determined by
echocardiographic-measured EOAi. As suggested by
other studies [8,26], the utilization of the measured
EOAi to define P-PtM may lead to an underestimation
of the impact of P-PtM on survival. Hence, it is reasonable
that no significant impact of P-PtM on postoperative
mortality was observed in our series. Moreover, the
measurement of LVMI in our study was performed by
M-mode echocardiography, which is regarded less ac-
curate than magnetic resonance imaging.
The improvement of a patient’s physical capacity was
not quantified in the present study (eg. the use of the
SF-36 questionnaire), and the impact of the moderate P-
PtM on patients’ quality of life is thereby questionable.
Beyond the preoperative LVEF and age, body mass index
is also an important factor that may have a significant
impact on postoperative outcomes. However, in our series,
only a small proportion of patients (11 patients) have a
body mass index above 25 kg/m2. Hence, the observed
effects of the moderate P-PtM on midterm outcomes after
AVR with a 17-mm Regent valve cannot be generalized to
obese patients. In addition, the small number of patients
with severe P-PtM in our series prevented our further
investigation of the long-term safety and effectiveness
of the 17-mm Regent valve.
Conclusions
Moderate P-PtM after implantation of a small mechanical
prosthesis at aortic position is associated with increased
midterm mortality and valve-related complications in pa-
tients with pre-existing LV dysfunction. Selected patients
with small aortic annulus can experience satisfactory clin-
ical results and midterm survival after isolated AVR with a
17-mm SJMR valve.
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